New triple-drug combo aims to shrink advanced head and neck tumors
NCT ID NCT04643379
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 29 times
Summary
This study tests a three-drug combination (olaparib, pembrolizumab, and carboplatin) as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix shrinks tumors better than the current standard therapy. About 30 adults with incurable disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.